Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication

PERUSE investigators

    Research output: Contribution to journalArticlepeer-review

    3 Scopus citations

    Fingerprint

    Dive into the research topics of 'Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication'. Together they form a unique fingerprint.

    Medicine & Life Sciences